 |
|
Chronic kidney disease in the BCR-ABL1-negative myeloproliferative neoplasm: a single-center retrospective study
Seung-Woo Baek, Ji Young Moon, Hyewon Ryu, Yoon-Seok Choi, Ik-Chan Song, Hyo-Jin Lee, Hwan-Jung Yun, Samyoung Kim, Deog-Yeon Jo
Korean J Intern Med. 2018;33(4):790-797. Published online 2017 Mar 17 DOI: https://doi.org/10.3904/kjim.2016.263
|
|
Citations to this article as recorded by
 Presence and Onset of Chronic Kidney Disease as a Factor Involved in the Poor Prognosis of Patients with Essential Thrombocythemia
Yoshinori Hashimoto, Hiromi Omura, Takayuki Tanaka, Manishekhar Kumar
Advances in Hematology.2024;[Epub] CrossRef Clonal Monocytosis of Renal Significance
Anuya A. Natu, Ishan Gupta, Nelson Leung, Mariam P. Alexander, Mrinal M. Patnaik
Kidney International.2024;[Epub] CrossRef Renal Impairment in Myeloproliferative Neoplasms: An Under-reported Complication
Rintu Sharma, Arihant Jain, Charanpreet Singh, Aditya Jandial, Deepesh Lad, Alka Khadwal, Gaurav Prakash, Ritambhra Nada, Raja Ramachandra, Neelam Varma, Pankaj Malhotra
Indian Journal of Hematology and Blood Transfusion.2024;[Epub] CrossRef Higher JAK2 V617F mutant allele burden in patients with chronic myeloproliferative neoplasms is associated with a higher prevalence of chronic kidney disease and unfavorable dynamics of kidney function over time
Marko Lucijanic, Petra Veic, Ivona Aric, Katarina Marija Tupek, Ena Soric, Anica Sabljic, Josipa Vlasac Glasnovic, Tajana Stoos-Veic, Ivan Krecak, Rajko Kusec
Annals of Hematology.2023; 102(7): 1955. CrossRef The spectrum of glomerular and vascular kidney pathology associated with myeloproliferative neoplasms
Thibaut d’Izarny-Gargas, Pierre Isnard, Idris Boudhabhay, David Buob, Anissa Moktefi, Charel Linster, Aurélie Hummel, Emmanuel Esteve, Vincent Audard, Hélène Lazareth, Nadine Maroun, Alexandre Hertig, Clément Gosset, Charlotte Jouzel, Sarah Permal, Camill
Kidney International.2023; 104(6): 1206. CrossRef Renal disease associated with chronic myeloproliferative neoplasms
Marko Lucijanic, Ivan Krecak, Rajko Kusec
Expert Review of Hematology.2022; 15(2): 93. CrossRef Lesson for the clinical nephrologist: renal involvement in a patient with polycythemia vera
Alon Bnaya, Aaron Ronson, Ofer Benjaminov, Linda Shavit
Journal of Nephrology.2022; 35(8): 2123. CrossRef Myeloproliferative Neoplasm and Myelodysplastic Syndrome-Associated Renal Disease: A Histopathological Report of Two Cases
Hristo Popov, Tatiana Koleva, George S Stoyanov, Peter Ghenev
Cureus.2022;[Epub] CrossRef Kidney Involvement in Patients With Chronic Myelomonocytic Leukemia or BCR-ABL–Negative Myeloproliferative Neoplasms
Julie Belliere, Magali Colombat, Clément Kounde, Christian Recher, David Ribes, Antoine Huart, Dominique Chauveau, Véronique Demas, Isabelle Luquet, Odile Beyne-Rauzy, Suzanne Tavitian, Stanislas Faguer
Kidney International Reports.2021; 6(3): 737. CrossRef Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms
Maike Büttner‐Herold, Carsten Sticht, Thorsten Wiech, Stefan Porubsky
Histopathology.2021; 78(5): 738. CrossRef Beneficial effect of ACE inhibitors on kidney function in polycythemia vera
Ivan Krečak, Martina Morić Perić, Ivan Zekanović, Hrvoje Holik, Božena Coha, Velka Gverić-Krečak, Marko Lucijanić
Wiener klinische Wochenschrift.2021; 133(15-16): 808. CrossRef Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry
Judith Gecht, Ioannis Tsoukakis, Kim Kricheldorf, Frank Stegelmann, Martine Klausmann, Martin Griesshammer, Holger Schulz, Wiebke Hollburg, Joachim R. Göthert, Katja Sockel, Florian H. Heidel, Norbert Gattermann, Christoph Maintz, Haifa K. Al-Ali, Uwe Pla
Cancers.2021; 13(16): 4086. CrossRef Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment
Ken Ogasawara, William B. Smith, Christine Xu, Jian Yin, Maria Palmisano, Gopal Krishna
Cancer Chemotherapy and Pharmacology.2020; 85(6): 1109. CrossRef Chronic kidney disease could be a risk factor for thrombosis in essential thrombocythemia and polycythemia vera
Ivan Krečak, Hrvoje Holik, Morić Perić Martina, Ivan Zekanović, Božena Coha, Velka Gverić-Krečak
International Journal of Hematology.2020; 112(3): 377. CrossRef Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis
Marko Lucijanic, Davor Galusic, Ivan Krecak, Martina Sedinic, Hrvoje Holik, Vlatka Perisa, Martina Moric Peric, Ivan Zekanovic, Tajana Stoos-Veic, Rajko Kusec
Annals of Hematology.2020; 99(12): 2779. CrossRef Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis
Paolo Strati, Maen Abdelrahim, Umut Selamet, Valda D. Page, Sherry A. Pierce, Srdan Verstovsek, Ala Abudayyeh
Annals of Hematology.2019; 98(7): 1611. CrossRef
|